DEXAMETHASONE SODIUM PHOSPHATE

Post-LOE

dexamethasone sodium phosphate

Bausch + Lomb

ANDAOPHTHALMIC, OTICSOLUTION/DROPS

Approved

Jul 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DEXAMETHASONE SODIUM PHOSPHATE (dexamethasone sodium phosphate) by Bausch + Lomb is clinical pharmacology dexamethasone sodium phosphate suppresses the inflammatory response to a variety of agents and it probably delays or slows healing. Approved for rheumatoid arthritis, rheumatoid arthritis, psoriasis and 7 more indications. First approved in 1996.

Drug data last refreshed 23h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Dexamethasone sodium phosphate suppresses the inflammatory response to a variety of agents and it probably delays or slows healing. No generally accepted explanation of these steroid properties has been advanced.

Indications (8)

Rheumatoid arthritis psoriasis asthma

Worked on DEXAMETHASONE SODIUM PHOSPHATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT02770807Phase 3Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Started Mar 2017

176 enrolled

Nervous System DiseaseGenetic Syndrome

NCT01255358Phase 2Completed

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Started Feb 2011

22 enrolled

Nervous System DisorderGenetic Syndrome